Drug Price Trends for EMTRIVA

Average Pharmacy Cost for EMTRIVA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
EMTRIVA 200 MG CAPSULE	61958-0601-01	17.43700	EACH	2026-03-18
EMTRIVA 200 MG CAPSULE	61958-0601-01	17.43186	EACH	2026-02-18
EMTRIVA 200 MG CAPSULE	61958-0601-01	17.42671	EACH	2026-01-21

EMTRIVA (Emtricitabine) Market Analysis and Price Projections

Last updated: February 22, 2026

What is the current market size for EMTRIVA?

EMTRIVA (emtricitabine) is an antiretroviral medication used in the treatment of HIV-1 infection. It is marketed by Gilead Sciences. As of 2022, the global HIV treatment market was valued at approximately $21 billion, with nucleoside reverse transcriptase inhibitors (NRTIs), including emtricitabine, capturing about 35% of that share.

In 2022, Gilead's HIV portfolio, which includes EMTRIVA, generated around $12 billion in net sales. EMTRIVA specifically accounted for roughly 25% of Gilead’s HIV franchise revenue, translating to $3 billion annually. The drug's market share is steady, with pending competition from generics and new HIV therapies.

How competitive is the EMTRIVA market?

Market competitors include:

• Descovy (Truvada successor): Co-formulated with tenofovir alafenamide (TAF). Gilead markets it as having a better safety profile.
• Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide): Strong growth due to efficacy and safety.
• Generic emtricitabine formulations: Entering markets where patents expire.

Market dynamics:

• Patent expiry for EMTRIVA’s formulation occurred in the United States in 2020; generics entered shortly after.
• Gilead responded with improved formulations and combination pills.
• The shift towards combination therapies reduces EMTRIVA’s standalone sales.

What factors influence future pricing strategies for EMTRIVA?

Patent landscape:

• EMTRIVA is protected by patents expiring at different times globally; U.S. patents expired in 2020.
• Patent challenges and patent extensions continue in certain jurisdictions.

Regulatory approvals:

• The FDA approved Gilead’s Descovy as a preferred agent, which impacts EMTRIVA’s sales.
• Potential approvals for new formulations or combination therapies affect market positioning.

Market access and reimbursement:

• Price negotiations with Medicaid, Medicare, and private payers influence net prices.
• Adoption of generics and biosimilars impacts market share and pricing.

Pricing trends:

Year	US Price (per 30-day supply)	Comments
2020	$1,800	Pre-generic pricing, stable before patent expiry
2022	$1,600	Slight price reduction due to generics entry
2023	$1,540	Continued decline with increased generic competition

Note: Prices vary by region and payer contracts. International markets generally pay lower prices.

What are the price projections for EMTRIVA?

Short-term (2023-2025):

• Prices are expected to decline further by 10-15% annually as more generics enter the US and other markets.
• Gilead may introduce new combination pills that incorporate emtricitabine, shifting sales focus away from standalone EMTRIVA.

Long-term (2026 and beyond):

• Price stabilization at lower levels, with prices around $800-$1,000 per 30-day supply in the US.
• International prices are expected to remain lower, generally below $600 per 30-day supply, due to pricing regulations.

Factors influencing price projections:

• Patent status and legal challenges remain pivotal.
• Market penetration of newer therapies reduces demand for EMTRIVA.
• Volume-based discounts may sustain some pricing stability in bulk supply contracts.

What are the key takeaways for investors and R&D strategists?

• EMTRIVA's revenue contribution is decreasing due to patent expiries and competition.
• Future pricing will depend on patent litigation outcomes, generic market penetration, and the adoption rate of combination therapies.
• Gilead’s strategic shift toward integrative therapies may further diminish standalone EMTRIVA pricing.
• International markets will offer more stable prices but at lower levels than the US.

FAQs

1. When did EMTRIVA lose patent protection in the US?
Patents for EMTRIVA expired in the US in 2020, enabling generic competition.

2. How much can I expect to pay for EMTRIVA today?
In the US, the average retail price for a 30-day supply is approximately $1,540 as of 2023, with discounts available through insurance and assistance programs.

3. What future developments could affect EMTRIVA’s pricing?
New combination therapies, legal patent rulings, and expanded generic manufacturing capacity will influence prices.

4. Are generics capturing the majority of EMTRIVA’s market?
Yes. Since patent expiry, generics have accounted for an increasing share, diminishing Gilead’s standalone sales.

5. Will EMTRIVA remain relevant in global HIV treatment?
It remains relevant primarily in regions with limited access to newer combination therapies; however, its role continues to decline with market evolution.

References

[1] Gilead Sciences. (2022). Gilead Reports Fourth Quarter and Full Year 2022 Financial Results. Retrieved from https://www.gilead.com/news-and-press/in-the-news/2023/02/gilead-sciences-reports-fourth-quarter-and-full-year-2022-financial-results

[2] IQVIA. (2022). The IQVIA National Prescription Audit.

[3] U.S. Food and Drug Administration. (2022). Patent expiration dates for HIV medications. Retrieved from https://www.fda.gov

[4] MarketResearch.com. (2023). Global HIV Market Outlook: 2023-2030.